Ann: Appendix 4C - quarterly, page-247

Imo the solution to get AHZ out of this tight spit is very simple; assuming the break even point is $40m revenue and they continue to grow at 20% Q on Q and flat growth for infusion 2018 fy total will be approximately $28m. At the same growth rate which is is very conservative fy 2019 should total approx $40m. This does not include any additional products, increased growth or additional infusion revenue. So the current figures are not that stark. Anyone could write a business case to attract equity, finance on these figures with a well proven product track record and pipeline. I have written business cases for approval of funds for returns with much less potential and of quantities sonar to what is required to keep AHZ a going concern. Surely our COD can achieve this, it is not a high risk venture if it is presented correctly. This is not as big a problem as it appears and requires some carefully planning and genuine effort.

The best of luck to all